Tracked deals
5
5 tracked deals across 2022-2025.
Private Equity Firm
Healthcare
Impilo
Stockholm, Sweden
Impilo is a Nordic investment company focused solely on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries, with an emphasis on positive and sustainable development of markets and communities.
- Focus Areas
- Pharmaceuticals, Medical technology, Healthcare services
- Website
- impilo.se
Recent pace
1
1 tracked deal announced in the last 12 months.
Deal mix
Buyout
5 buyout
Impilo Acquisition Volume by Year
Last 4 years
Supporting Data
Recent Transactions
-
October 22, 2025
- Buyer
- Impilo
- Target
- Oticon Medical
- Seller
- Demant A/S
- Industry
- Medical Devices
- Location
- Denmark
- Type
- Buyout
Impilo has agreed to acquire Oticon Medical, a global bone-anchored hearing solutions company, from Demant A/S. The deal is intended to support Oticon Medical’s transition to a standalone company and accelerate growth through next-generation technologies, with closing expected no later than the end of Q1 2026.
-
January 24, 2025
- Buyer
- KKR, Impilo, Immedica management
- Target
- Immedica Pharma
- Seller
- Existing Impilo limited partners
- Industry
- Pharmaceuticals
- Location
- Stockholm, Sweden
- Type
- Buyout
KKR and Nordic healthcare investor Impilo have completed a joint acquisition of Stockholm-based Immedica Pharma, with Immedica management reinvesting alongside the new owners. Immedica is a commercial-stage pharmaceutical company focused on rare and specialty diseases (notably hematology, oncology and genetic/metabolic disorders) with ~€100m revenue and more than 120 employees; CVC Credit provided debt financing and Impilo used a single-asset continuation fund supported by secondary investors.
-
September 9, 2024
- Buyer
- Scantox Group, Impilo
- Target
- Gentronix Ltd
- Industry
- Healthcare Services
- Location
- England, United Kingdom
- Type
- Buyout
Scantox Group, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK-based GLP-compliant genetic toxicology contract research organization (CRO). Gentronix is being integrated into Scantox Group to expand its genetic toxicology and genomic safety capabilities and to better support pre-IND enabling studies.
-
February 3, 2022
- Buyer
- Impilo, SHS Capital
- Target
- Lowenco A/S
- Seller
- Founder and owners
- Industry
- Medical Devices
- Location
- Denmark
- Type
- Buyout
Nordic investor Impilo and German healthcare-focused investor SHS Capital acquired Lowenco A/S from its founder and owners. Lowenco, headquartered in Vamdrup, Denmark, manufactures modular ultra-low temperature (ULT) storage solutions for the biopharma and pharmaceutical industries; management remains in place and Michael Berg will be appointed chairman of the board.
-
January 1, 2022
Impilo, a Nordic healthcare-focused investment company, has acquired a majority stake in tandlægen.dk, Denmark’s leading dental clinic chain. The clinic leaders and management have reinvested part of their proceeds and will partner with Impilo to support further growth, quality improvements and digitalisation across the chain’s 52 clinics and ~800 employees.
Related Acquisition Pages
Selling a company? Get in front of buyers like Impilo
Turn tracked acquisition activity into an outreach-ready buyer list.